Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) drugs have been approved for treatment of patients with advanced non-small cell lung cancer (NSCLC) (1–3). Here, PDCD1 is linked to non-small cell lung carcinoma.